🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New #JITC article: Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020 bit.ly/43lQM8O Paolo A. Ascierto

Meanwhile the new generation of physicians come looking like this. Wearing a suit is a sign of respect for the patient and the craft. Also respect to colleagues. The patient that prices your suit erroneously has the means to buy that same suit.

Gut microbiota from Phase III JCOG2007 (NIPPON) trial of 1L pembro/chemo vs nivo + ipi/chemo in NSCLC JTO & JTO CRR. Fusicatenibacter & Butyricicoccus associated with longer OS, fewer AEs, more benefit with nivo/ipi. Microbiome impact could be massive. jto.org/article/S1556-…

consistently working The Angeles Clinic to find answers - ADC are partners in the future of IO for solid tumors #Melanoma #NSCLC

Really looking forward to this ANCO MOASC IO Symposium with experts from all over CA! Hope you will join us to learn from Sumanta K. Pal, MD, FASCO Omid Hamid MD Pauline Funchain and so many more!!

Two decades here at The Angeles Clinic with MarkFariesMD fighting #Melanoma at Cedars-Sinai , ProvidenceSaintJohn #MelanomaAwarenessMonth no different. Real breakthroughs together with more #worktodo #clinicaltrials [email protected]

"Massive Financial Contraction" and "Micro-biotech Environment Cratered" are the new realty phrases in drug development. This is a real conversation with Sponsor. Looking for answers.... #worktodo #TGIF

#MelanomaAwarenessMonth proud to collaborate AIM at Melanoma Foundation (15th year ) May 22 4pm EST with The Angeles Clinic Inderjit Mehmi MarkFariesMD Justin Moyers Cancer at Cedars-Sinai aimatmelanoma.org/melanoma-learn…

Happy Birthday to this absolute LEGEND, Jeffrey Weber MD. Jeff, we miss you dearly but work to meet your example and beat cancer with the roadmap you left for us. #melanomaresearch #worktodo #immunotherapy NYU Langone Health The Angeles Clinic Moffitt Cancer Center Melanoma Research AIM at Melanoma Foundation

Running around ASCO #ASCO25 and utilizing Uber Uber Support ignorant to the penalties that exist for City of Chicago travel. Thankfully there was no charge for the air and oxygen

Carnage continues ASCO #ASCO25 meeting with pharmacist partners with most small bio delivering bad news of trial early termination or restriction/termintion of expansion cohorts. #earlydevelopment

Thank you to OncologyEducation for the ability to discuss #ASCO25 ASCO #melanoma abstracts of import oncologyeducation.com/podium-to-prac…

A point of clarification on the mayoral election. I don’t believe that money can buy elections. Kamala Harris outspent Donald J. Trump massively and lost in a veritable landslide. That said, being able to fund a campaign is table stakes for running for office. When I wrote

#melanoma & Cutaneous Malignancies 2/21/26 #LosAngeles FREE REG CODE: HAMID IN-PERSON gotoper.com/courses/intern…)

#ScienceSaturday 🏃‍♂️🧬 Can exercise really help fight #cancer? 📢 A new study in Cell shows exercise rewires the gut #microbiome to enhance immune responses against tumors. ➡️ Catherine Phelps et al. found exercise increases levels of a microbiota-derived metabolite called

That feeling when 7+ years of work lands on the front page of NEJM—and one of the people I respect most, Kohei shitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn Memorial Sloan Kettering Cancer Center

RP1 (vusolimogene oderparepvec) in PD1/CTLA failed #melanoma data with ongoing phase 3 trial and FDA PDUFA 7-22 - safe, effective option for patients. soon for other solid tumors Journal of Clinical Oncology Replimune accruing The Angeles Clinic ascopubs.org/doi/pdf/10.120…

LAG-3 blockade may help with #Parkinsonsdisease Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein Nature Communications targets for therapeutic strategies aimed at preventing neurodegeneration in Parkinson’s disease and related α-synucleinopathies

The FDA Said No — Now We Need Your Voice Melanoma Research Replimune RP-1 #melanoma aimatmelanoma.org/the-fda-said-n…